Kartik Pandurang Jadhav

Dr. Kartik Pandurang Jadhav


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of Cardiology Cases
Verified
Journal Article
Closed access
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
PPPraveen G Pai
Praveen G Pai

2 February 2021 in Indian Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
PJPankaj Jariwala
Pankaj Jariwala
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
SKSaratchandra Koduganti
Saratchandra Koduganti

1 November 2020 in Indian Heart Journal
Verified
Journal Article
Open access
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
PJPankaj Jariwala
Pankaj Jariwala

1 September 2021 in Indian Heart Journal
Verified
Journal Article
Open access
PJPankaj Jariwala
Pankaj Jariwala
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
APArshad Punjani
Arshad Punjani
HBhari kishan boorugu
hari kishan boorugu
AMAjay Reddy Mari
Ajay Reddy Mari
Objectives: We evaluated the efficacy and safety of dapagliflozin, a SGLT2i along with ARNI in refractory HFrEF irrespective of their diabetic status. Methods: We performed a retrospective analysis of 104 symptomatic patients of HFrEF despite of optimal medical management with ARNI between January-June 2020. Despite the optimal GDMT, dapagliflozin, SGLT2i was added inpatients withrefractory heart failure. At 6-months follow-up, the primary outcome was change in left ventricular ejection fraction, and secondary outcomes included changes in NYHA functional class, vital parameters, renal function, potassium levels, and NT-pro BNP levels. Results: The primary outcomeat 6-months follow-up was a mean change in left ventricular ejection fraction (LVEF) +9.00 +/- 0.62 (p < 0.001). The secondary outcome was a significant improvement (69%) in median NYHA functional class by 2.3 (95% Confidence interval 2.245-2.355) with 92.6% of patients were in NYHA class I and 7.4% were in NYHA class II.Diabetic subgroup reached the HbA1C goal of <7%. None of them had either symptomatic hypotension, hypoglycaemia, dyselectrolaemia, and decline in renal function. The drug was well received by most of the patients. Conclusions: Dapagliflozin, an SGLT2i, should be used in symptomatic, refractory HFrEF patients despite the use of ARNI. The combination of ARNI and SGLT2i is well tolerated, but large, randomized trials are needed to prove this hypothesis. (C) 2021 Cardiological Society of India. Published by Elsevier B.V.

13 April 2022 in Indian Heart Journal
Verified
Journal Article
Open access
PJPankaj Jariwala
Pankaj Jariwala
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
Angiographically, a “dual LAD” is described as two distinct arteries supplying the vascular territory of the LAD in parts, identified as the short LAD/LAD1 and the long LAD/LAD2. Using an easy-to-understand three-step approach, Jariwala et al unveiled a novel classification strategy for dual LAD systems in an attempt to decrease ambiguity in diagnosis and management of the anomaly. As part of our research, we looked at a wide range of published cases and case series in the literature, and also those reported from our hospital. In our novel classification system, we divide dual LADs into three main groups based on their origin and vascular territory, each of which is further divided into subgroups based on the course of LAD1/LAD2 and the variable feature that is a distinguishing attribute of the type of anomaly to be specified.

23 December 2020 in Journal of Cardiology and Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
PJPankaj V Jariwala
Pankaj V Jariwala
Introduction: One of the major complications among COVID-19 patients include cardiac arrhythmias. Commonest arrhythmia is sinus tachycardia which is usually associated with palpitation causing discomfort to patients. In this study, we present a comparative study of use of Ivabradine vs. Carvedilol for sinus tachycardia in post-COVID-19 infected patients. Method: 50 consecutive recovered COVID-19 patients with sinus tachycardia were included in this open labelled RCT. 25 patients received Ivabradine and remaining 25 received Carvedilol. Single therapy non-responders were treated with Ivabradine with Atorvastatin. Results: The mean age of all patients is 48.8±7.66 years (Males 49.5 ± 7.21 years; Females 47.68 ± 8.23 years). The mean heart rate (MHR) of all patients is 125.52 ± 9.07/min (Males 125.67 ± 8.78/min; Females 125.26 ± 9.5/min). After five days of single drug therapy the mean drop in the heart rate was 35.04 ± 10.55/min (Males 34.41 ± 9.71/min; Females 36.05 ± 11.72/min), resulting in 27.88 ± 8.11% (Males 27.38 ± 7.56%; Females 28.69 ± 8.89%) reduction in MHR. Among the two groups, the Carvedilol group showed improvement of MHR in 14(56%) patients; whereas in Ivabradine group 18(72%) patients improved out of 25 patients each (p: 0.2385). In the Carvedilol group the MHR reduced from 128.6 ± 8.44 to 95.68 ± 10.63 (p < 0.001), which is statistically significant; similarly, the Ivabradine group showed a MHR from 122.44 ± 8.62 to 85.28 ± 10.52 (p < 0.001). The monotherapy therapy non-responders were treated with dual-therapy of (Ivabradine + Atorvastatin). Discussion: Ivabradine is more effective in controlling heart rate compared to Carvedilol. Also, Ivabradine group scores very well in ‘patient-satisfaction’ with regards to symptom (palpitation) relief. Conclusion: The COVID-19 sequelae of sinus tachycardia can be better controlled with Ivabradine when compared to Carvedilol.